Zinplava OverviewBezlotoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection. Actoxumab and bezlotoxumab are fully human monoclonal antibodies which bind Clostridium difficile (C diff) toxins A and B, respectively. This drug, along with actoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck Sharp &...
Read more Zinplava Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Bezlotoxumab
Recent Zinplava Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 1000ml/40ml
NDC Database Records for Zinplava: (1 result)Sorted by National Drug Code
- 0006-3025 Zinplava 25 mg/ml Intravenous Injection, Solution by Merck Sharp & Dohme Corp.